Treating foodborne illness

Infectious Disease Clinics of North America

Volumn 27, Issue 3, 2013, Pages 555-576

  Steiner, Theodore ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antibiotics; Antidiarrheals; Antiemetics; Diarrhea

Indexed keywords

ALBENDAZOLE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ATROPINE; ATROPINE PLUS DIPHENOXYLATE; ATTAPULGITE; BISMUTH SALT; CORTICOSTEROID; DICYCLOVERINE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; HYOSCYAMINE; KAOLIN PECTIN; LEVAMISOLE; LOPERAMIDE; MEBENDAZOLE; METOCLOPRAMIDE; NICLOSAMIDE; ONDANSETRON; OPIATE ANTAGONIST; PRAZIQUANTEL; PROBIOTIC AGENT; PROCHLORPERAZINE; PYRANTEL; QUINIDINE; SCOPOLAMINE; SCOPOLAMINE BUTYL BROMIDE; SEROTONIN ANTAGONIST; SPASMOLYTIC AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUPRESSURE; ACUPUNCTURE; AKATHISIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ASCARIASIS; BACILLUS CEREUS; BOTULISM; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM PERFRINGENS; DIARRHEA; DYSENTERY; DYSPEPSIA; ENTEROCOLITIS; EXTRAPYRAMIDAL SYMPTOM; FOOD INTAKE; FOOD POISONING; GASTROINTESTINAL INFECTION; HELMINTHIASIS; HEMORRHAGIC COLITIS; HUMAN; LISTERIA MONOCYTOGENES; MORBIDITY; MORTALITY; MUSCLE RIGIDITY; NAUSEA; NAUSEA AND VOMITING; NUTRIENT SUPPLY; ORAL REHYDRATION THERAPY; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; SYMPTOMATOLOGY; TAENIASIS; TOXOPLASMA GONDII; TRICHURIASIS; TYPHOID FEVER; VIRAL GASTROENTERITIS; YERSINIA ENTEROCOLITICA;

ANTIBIOTICS; ANTIDIARRHEALS; ANTIEMETICS; DIARRHEA;

ADULT; ANTI-INFECTIVE AGENTS; ANTIDIARRHEALS; ANTIEMETICS; CHILD; FLUID THERAPY; FOODBORNE DISEASES; HUMANS; PARASYMPATHOLYTICS;

EID: 84883551455     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2013.05.006     Document Type: Review

References (87)

1. Le Loir Y., Baron F., Gautier M. Staphylococcus aureus and food poisoning. Genet Mol Res 2003, 2(1):63-76.
2. Stenfors Arnesen L.P., Fagerlund A., Granum P.E. From soil to gut: Bacillus cereus and its food poisoning toxins. FEMS Microbiol Rev 2008, 32(4):579-606.
3. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep 2011, 60(RR-3):1-18.
4. Carr M.E., McKendrick G.D., Spyridakis T. The clinical features of infantile gastroenteritis due to rotavirus. Scand J Infect Dis 1976, 8(4):241-243.
5. Uhnoo I., Olding-Stenkvist E., Kreuger A. Clinical features of acute gastroenteritis associated with rotavirus, enteric adenoviruses, and bacteria. Arch Dis Child 1986, 61(8):732-738.
6. Bresee J.S., Marcus R., Venezia R.A., et al. The etiology of severe acute gastroenteritis among adults visiting emergency departments in the United States. JInfect Dis 2012, 205(9):1374-1381.
7. Centers for Disease Control and Prevention (CDC) Recognition of illness associated with the intentional release of a biologic agent. MMWR Morb Mortal Wkly Rep 2001, 50(41):893-897.
8. Wong C.K., Hung P., Lee K.L., et al. Features of ciguatera fish poisoning cases in Hong Kong 2004-2007. Biomed Environ Sci 2008, 21(6):521-527.
9. Ullrich S., Bremer P., Neumann-Grutzeck C., et al. Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study. PLoS One 2013, 8(2):e55278.
10. Griffin P.M., Ostroff S.M., Tauxe R.V., et al. Illnesses associated with Escherichia coli O157:H7 infections. A broad clinical spectrum. Ann Intern Med 1988, 109(9):705-712.
11. Thriemer K., Ley B.B., Ame S.S., et al. Clinical and epidemiological features of typhoid fever in Pemba, Zanzibar: assessment of the performance of the WHO case definitions. PLoS One 2012, 7(12):e51823.
12. Gagnon M.P., Bissonnette P., Deslandes L.M., et al. Glucose accumulation can account for the initial water flux triggered by Na+/glucose cotransport. Biophys J 2004, 86(1 Pt 1):125-133.
13. Multicentre evaluation of reduced-osmolarity oral rehydration salts solution. International Study Group on Reduced-osmolarity ORS solutions. Lancet 1995, 345(8945):282-285.
14. Santosham M., Fayad I., Abu Zikri M., et al. Adouble-blind clinical trial comparing World Health Organization oral rehydration solution with a reduced osmolarity solution containing equal amounts of sodium and glucose. JPediatr 1996, 128(1):45-51.
15. Gregorio G.V., Gonzales M.L., Dans L.F., et al. Polymer-based oral rehydration solutionfor treating acute watery diarrhoea. Cochrane Database Syst Rev 2009, (2). CD006519.
16. Lazzerini M., Ronfani L. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev 2013, (1). CD005436.
17. Salvatore S., Hauser B., Devreker T., et al. Probiotics and zinc in acute infectious gastroenteritis in children: are they effective?. Nutrition 2007, 23(6):498-506.
18. Mayo-Wilson E., Imdad A., Herzer K., et al. Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis. BMJ 2011, 343:d5094.
19. Fischer Walker C.L., Black R.E. Micronutrients and diarrheal disease. Clin Infect Dis 2007, 45(Suppl 1):S73-S77.
20. Moore S.R., Lima N.L., Soares A.M., et al. Prolonged episodes of acute diarrhea reduce growth and increase risk of persistent diarrhea in children. Gastroenterology 2010, 139(4):1156-1164.
21. Oria R.B., Patrick P.D., Zhang H., et al. APOE4 protects the cognitive development in children with heavy diarrhea burdens in Northeast Brazil. Pediatr Res 2005, 57(2):310-316.
22. Guarino A., Albano F., Ashkenazi S., et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. JPediatr Gastroenterol Nutr 2008, 46(Suppl 2):S81-S122.
23. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455.
24. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011, 14(6):581-587.
25. Johnston B.C., Goldenberg J.Z., Vandvik P.O., et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011, (11). CD004827.
26. Szajewska H., Mrukowicz J.Z. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. JPediatr Gastroenterol Nutr 2001, 33(Suppl 2):S17-S25.
27. Riddle M.S., Arnold S., Tribble D.R. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis. Clin Infect Dis 2008, 47(8):1007-1014.
28. Butler T. Loperamide for the treatment of traveler's diarrhea: broad or narrow usefulness?. Clin Infect Dis 2008, 47(8):1015-1016.
29. Smith G.S., Blaser M.J. Fatalities associated with Campylobacter jejuni infections. JAMA 1985, 253(19):2873-2875.
30. Bell B.P., Griffin P.M., Lozano P., et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997, 100(1):E12.
31. Koo H.L., Koo D.C., Musher D.M., et al. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009, 48(5):598-605.
32. Baker D.E. Loperamide: a pharmacological review. Rev Gastroenterol Disord 2007, 7(Suppl 3):S11-S18.
33. Steffen R. Worldwide efficacy of bismuth subsalicylate in the treatment of travelers' diarrhea. Rev Infect Dis 1990, 12(Suppl 1):S80-S86.
34. DuPont H.L., Ericsson C.D., Farthing M.J., et al. Expert review of the evidence base for prevention of travelers' diarrhea. JTravel Med 2009, 16(3):149-160.
35. Shlim D.R. Update in traveler's diarrhea. Infect Dis Clin North Am 2005, 19(1):137-149.
36. Lehert P., Cheron G., Calatayud G.A., et al. Racecadotril for childhood gastroenteritis: an individual patient data meta-analysis. Dig Liver Dis 2011, 43(9):707-713.
37. Szajewska H., Ruszczynski M., Chmielewska A., et al. Systematic review: racecadotril in the treatment of acute diarrhoea in children. Aliment Pharmacol Ther 2007, 26(6):807-813.
38. Freedman S.B., Adler M., Seshadri R., et al. Oral ondansetron for gastroenteritis in a pediatric emergency department. NEngl J Med 2006, 354(16):1698-1705.
39. Carter B., Fedorowicz Z. Antiemetic treatment for acute gastroenteritis in children: an updated Cochrane systematic review with meta-analysis and mixed treatment comparison in a Bayesian framework. BMJ Open 2012, 2(4). 10.1136/bmjopen, 2011-000622.
40. Fedorowicz Z., Jagannath V.A., Carter B. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev 2011, (9). CD005506.
41. Al-Ansari K., Alomary S., Abdulateef H., et al. Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis. JPediatr Gastroenterol Nutr 2011, 53(2):156-160.
42. Patka J., Wu D.T., Abraham P., et al. Randomized controlled trial of ondansetron vs. prochlorperazine in adults in the emergency department. West J Emerg Med 2011, 12(1):1-5.
43. Uhlig U., Pfeil N., Gelbrich G., et al. Dimenhydrinate in children with infectious gastroenteritis: a prospective, RCT. Pediatrics 2009, 124(4):e622-e632.
44. Lee J., Oh H. Ginger as an antiemetic modality for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Oncol Nurs Forum 2013, 40(2):163-170.
45. Anders E.F., Findeisen A., Lode H.N., et al. Acupuncture for treatment of acute vomiting in children with gastroenteritis and pneumonia. Klin Padiatr 2012, 224(2):72-75.
46. Tacket C.O., Shandera W.X., Mann J.M., et al. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984, 76(5):794-798.
47. Palafox N.A., Jain L.G., Pinano A.Z., et al. Successful treatment of ciguatera fish poisoning with intravenous mannitol. JAMA 1988, 259(18):2740-2742.
48. Schnorf H., Taurarii M., Cundy T. Ciguatera fish poisoning: a double-blind randomized trial of mannitol therapy. Neurology 2002, 58(6):873-880.
49. Kollaritsch H., Paulke-Korinek M., Wiedermann U. Traveler's diarrhea. Infect Dis Clin North Am 2012, 26(3):691-706.
50. Dryden M.S., Gabb R.J., Wright S.K. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 1996, 22(6):1019-1025.
51. Neill M.A., Opal S.M., Heelan J., et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 1991, 114(3):195-199.
52. Onwuezobe I.A., Oshun P.O., Odigwe C.C. Antimicrobials for treating symptomatic non-typhoidal Salmonella infection. Cochrane Database Syst Rev 2012, (11). CD001167.
53. Gordon M.A. Salmonella infections in immunocompromised adults. JInfect 2008, 56(6):413-422.
54. Uysal G., Sokmen A., Vidinlisan S. Clinical risk factors for fatal diarrhea in hospitalized children. Indian J Pediatr 2000, 67(5):329-333.
55. Metzler A.E., Burri H.R. The etiology of "malignant catarrhal fever" originating in sheep: serological findings in cattle and sheep with ruminant gamma herpesviruses. Tierarztl Prax 1991, 19(2):135-140.
56. Rahman M., Shoma S., Rashid H., et al. Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin. JHealth Popul Nutr 2007, 25(2):158-167.
57. Fernandez-Cruz A., Munoz P., Mohedano R., et al. Campylobacter bacteremia: clinical characteristics, incidence, and outcome over 23 years. Medicine (Baltimore) 2010, 89(5):319-330.
58. Ternhag A., Asikainen T., Giesecke J., et al. Ameta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis 2007, 44(5):696-700.
59. Wang X., Zhao S., Harbottle H., et al. Antimicrobial resistance and molecular subtyping of Campylobacter jejuni and Campylobacter coli from retail meats. JFood Prot 2011, 74(4):616-621.
60. Beier R.C., Poole T.L., Brichta-Harhay D.M., et al. Disinfectant and antibiotic susceptibility profiles of Escherichia coli O157:H7 strains from cattle carcasses, feces, and hides and ground beef from the United States. JFood Prot 2013, 76(1):6-17.
61. Wong C.S., Jelacic S., Habeeb R.L., et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. NEngl J Med 2000, 342(26):1930-1936.
62. Ikeda K., Ida O., Kimoto K., et al. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999, 52(6):357-362.
63. Lapeyraque A.L., Malina M., Fremeaux-Bacchi V., et al. Eculizumab in severe Shiga-toxin-associated HUS. NEngl J Med 2011, 364(26):2561-2563.
64. Frank C., Werber D., Cramer J.P., et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. NEngl J Med 2011, 365(19):1771-1780.
65. Corogeanu D., Willmes R., Wolke M., et al. Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German outbreak. BMC Microbiol 2012, 12:160.
66. Bielaszewska M., Idelevich E.A., Zhang W., et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 2012, 56(6):3277-3282.
67. Geerdes-Fenge H.F., Lobermann M., Nurnberg M., et al. Ciprofloxacin reduces the risk of hemolytic uremic syndrome in patients with Escherichia coli O104:H4-associated diarrhea. Infection 2013, 41(3):669.
68. Nitschke M., Sayk F., Hartel C., et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 2012, 307(10):1046-1052.
69. Menne J., Nitschke M., Stingele R., et al. Validation of treatment strategies for enterohaemorrhagicEscherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012, 345:e4565.
70. Granados C.E., Reveiz L., Uribe L.G., et al. Drugs for treating giardiasis. Cochrane Database Syst Rev 2012, (12). CD007787.
71. Rossignol J.F., Kabil S.M., el-Gohary Y., et al. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin Gastroenterol Hepatol 2006, 4(3):320-324.
72. Rossignol J.F., Hidalgo H., Feregrino M., et al. Adouble-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998, 92(6):663-666.
73. Amadi B., Mwiya M., Sianongo S., et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect Dis 2009, 9:195.
74. Abubakar I., Aliyu S.H., Arumugam C., et al. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev 2007, (1). CD004932.
75. Carr A., Marriott D., Field A., et al. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998, 351(9098):256-261.
76. Gonzales M.L., Dans L.F., Martinez E.G. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev 2009, (2). CD006085.
77. Boonmar S., Morita Y., Fujita M., et al. Serotypes, antimicrobial susceptibility, and gyr A gene mutation of Campylobacter jejuni isolates from humans and chickens in Thailand. Microbiol Immunol 2007, 51(5):531-537.
78. Thakur S., Zhao S., McDermott P.F., et al. Antimicrobial resistance, virulence, and genotypic profile comparison of Campylobacter jejuni and Campylobacter coli isolated from humans and retail meats. Foodborne Pathog Dis 2010, 7(7):835-844.
79. Guerrant R.L., Van Gilder T., Steiner T.S., et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001, 32(3):331-351.
80. Thabane M., Simunovic M., Akhtar-Danesh N., et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol 2010, 105(4):933-939.
81. Zanini B., Ricci C., Bandera F., et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol 2012, 107(6):891-899.
82. Clark W.F., Sontrop J.M., Macnab J.J., et al. Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157:H7: a prospective cohort study. BMJ 2010, 341:c6020.
83. Kalra V., Chaudhry R., Dua T., et al. Association of Campylobacter jejuni infection with childhood Guillain-Barre syndrome: a case-control study. JChild Neurol 2009, 24(6):664-668.
84. Garcia Rodriguez L.A., Ruigomez A., Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 2006, 130(6):1588-1594.
85. Fryden A., Bengtsson A., Foberg U., et al. Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study. BMJ 1990, 301(6764):1299-1302.
86. Gilbert R.E., See S.E., Jones L.V., et al. Antibiotics versus control for toxoplasma retinochoroiditis. Cochrane Database Syst Rev 2002, (1). CD002218.
87. Vila J., Ruiz J., Gallardo F., et al. Aeromonas spp. and traveler's diarrhea: clinical features and antimicrobial resistance. Emerg Infect Dis 2003, 9(5):552-555.